Tenderwize
Retour à la recherche

Open-house rebate agreement for Betahistine

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Nov 30, 2027 · 459 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Betahistin (ATC-Code nach WHO: N07CA01)

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

Structured data says electronic submission is not allowed, while the notice says communication and transmission occur e...

The notice refers to project-room documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfrist...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Betahistine (ATC code N07CA01).
  • Open-house participation model with contract conclusion available to all interested and eligible pharmaceutical companies during the participation period.
Afficher le résumé complet

This is an open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for Betahistine (ATC N07CA01) with AOK PLUS. The procedure is open to all interested pharmaceutical companies that meet the stated participation conditions. No contract value is stated, minimum purchase volumes are not guaranteed, and no individual negotiations or exclusivity apply. Participation documents are available via DTVP, but the extracted procurement documents themselves were not provided for analysis.

Risques

Structured data says electronic submission is not allowed, while the notice says communication and transmission occur e...

The notice refers to project-room documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfrist...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company must have its seat in Germany, another EU Member State, or another EEA Contracting State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical companies for the offered medicines.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Betahistine

Non-exclusive pharmaceutical rebate agreement for medicines containing Betahistine (ATC N07CA01). The lot is described as an open-house model, so any eligible pharmaceutical company may join during the participation period. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volumes are stated. Performance/place of use is Germany, specifically Dresden in Saxony, according to the structured data.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jan 2026 - Nov 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 30, 2027

Détails de la procédure

Date de publication
23 Nov 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
778877-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30